Renal Macrocystic Disease

Gene: SEC63

Green List (high evidence)

SEC63 (SEC63 homolog, protein translocation regulator)
EnsemblGeneIds (GRCh38): ENSG00000025796
EnsemblGeneIds (GRCh37): ENSG00000025796
OMIM: 608648, Gene2Phenotype
SEC63 is in 6 panels

2 reviews

Chirag Patel (Genetic Health Queensland)

Green List (high evidence)

CLINGEN assessed as DEFINITIVE (2020)

SEC63 was FIRST reported in relation to autosomal dominant polycystic liver disease (ADPLD) in 2004 (Davila et al., PMID 15133510). ADPLD due to SEC63 mutations (ADPLD-SEC63) is diagnosed in adults with a family history of liver cysts, under age 40 with any number of liver cysts and individuals over the age of 40 with four or more liver cysts. Women are associated with more severe course of disease, and kidney cysts are present in approximately 28-35% of cases, but in these cases the kidney disease is mild with no association with progression to end stage renal disease (PMID 20408995). At least twenty unique variants (e.g. nonsense, frameshift, splice site, missense) have been reported in humans. Evidence supporting this gene-disease relationship includes case-level data, segregation data, population data and experimental data. Summary of Case Level Data: 12 POINTS. Variants in this gene have been reported in at least 19 probands and in at least four publications (PMID 15133510, PMID 16835903, PMID 20095989, PMID 28375157). Variants in this gene segregated with disease in at least 24 additional family members. More evidence is available in the literature, but the maximum score for genetic evidence (12 pts.) has been reached. The mechanism for disease is heterozygous loss of function (PMID 15133510, PMID 20095989), with experimental evidence suggesting endoplasmic reticulum stress with induction of the unfolded protein response (UPR) and association with aberrant polycystin 1 (PC1) post-translational modifications leading to cystogenesis (PMID 22864019, PMID 25844898). This gene-disease association is supported by expression studies in cell models, zebrafish models, and mouse models (PMID 21685914, PMID 22864019, PMID 25844898). In summary, SEC63 is definitively associated with AUTOSOMAL DOMINANT POLYCYSTIC LIVER DISEASE. This has been repeatedly demonstrated in both the research and clinical diagnostic settings, and has been upheld over time.
Created: 25 Nov 2022, 4:45 a.m. | Last Modified: 25 Nov 2022, 4:45 a.m.
Panel Version: 0.59
Renal cysts not a key or common feature seen in these patients. If this PLD gene is in the panel, then we should have all the PLD genes, where very occasional renal cysts can be seen.
Created: 23 Dec 2019, 3:37 a.m. | Last Modified: 23 Dec 2019, 3:39 a.m.
Panel Version: 0.13

Mode of inheritance
MONOALLELIC, autosomal or pseudoautosomal, NOT imprinted

Phenotypes
Polycystic liver disease 2; OMIM #617004

Zornitza Stark (Victorian Clinical Genetics Services; Australian Genomics)

Red List (low evidence)

Comment on list classification: Discussed with Chirag Patel: we should have a consistent approach to all liver cystic disease genes. Renal cysts are not a key feature, therefore Red for this panel.
Created: 23 Dec 2019, 3:39 a.m. | Last Modified: 23 Dec 2019, 3:39 a.m.
Panel Version: 0.13
Renal cysts reported in some individuals; no significant renal impairment.
Sources: Expert list
Created: 21 Dec 2019, 7:27 a.m.

Mode of inheritance
MONOALLELIC, autosomal or pseudoautosomal, NOT imprinted

Phenotypes
Polycystic liver disease 2, MIM#617004

Publications

Details

Mode of Inheritance
MONOALLELIC, autosomal or pseudoautosomal, NOT imprinted
Sources
  • Expert Review Green
  • Expert list
Phenotypes
  • Polycystic liver disease 2, MIM#617004
OMIM
608648
Clinvar variants
Variants in SEC63
Penetrance
None
Publications
Panels with this gene

History Filter Activity

25 Nov 2022, Gel status: 3

Entity classified by Genomics England curator

Chirag Patel (Genetic Health Queensland)

Gene: sec63 has been classified as Green List (High Evidence).

23 Dec 2019, Gel status: 1

Entity classified by Genomics England curator

Zornitza Stark (Victorian Clinical Genetics Services; Australian Genomics)

Gene: sec63 has been classified as Red List (Low Evidence).

21 Dec 2019, Gel status: 3

Entity classified by Genomics England curator

Zornitza Stark (Victorian Clinical Genetics Services; Australian Genomics)

Gene: sec63 has been classified as Green List (High Evidence).

21 Dec 2019, Gel status: 3

Entity classified by Genomics England curator

Zornitza Stark (Victorian Clinical Genetics Services; Australian Genomics)

Gene: sec63 has been classified as Green List (High Evidence).

21 Dec 2019, Gel status: 1

Created, Added New Source, Set mode of inheritance, Set publications, Set Phenotypes

Zornitza Stark (Victorian Clinical Genetics Services; Australian Genomics)

gene: SEC63 was added gene: SEC63 was added to Renal macrocystic disease_KidGen_VCGS. Sources: Expert list Mode of inheritance for gene: SEC63 was set to MONOALLELIC, autosomal or pseudoautosomal, NOT imprinted Publications for gene: SEC63 were set to 15133510 Phenotypes for gene: SEC63 were set to Polycystic liver disease 2, MIM#617004 Review for gene: SEC63 was set to GREEN